The SME instrument is part of the European Innovation Council pilot (EIC pilot) that was launched as part of the Horizon 2020 Work programme 2018-2020 to provide funding to high-potential innovation developed by SMEs. The SME instrument aims to boost breakthrough ideas with the potential to create entirely new markets or revolutionise existing ones.
In this context, the novelty and the potential social and economic impact of our AGLYC project for the development of The First In Vitro Diagnostic Device for the Early Detection of Cardiac Ischemia has been acknowledged by the H2020 Programme through the SME instrument funding. We have obtained this phase II of the SME Instrument in the October 2018 call, after receiving the phase I in May of the same year, both at the first attempt.
Through this SME Instrument phase II, GlyCardial Diagnostics will receive 1.9M€ that will be used to carry out the clinical validation of the novel in vitro test for the early detection of cardiac ischemia.